By Dr Georgia Jane McCaughan

Journal articles

Gration B; Wellard C; Moore E; Mollee P; Shetty A; Forsyth C; Heenan J; Kerridge I; McQuilten Z; Wood E; Spencer A; McCaughan G, 2026, 'Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia', Blood Cancer Journal, http://dx.doi.org/10.1038/s41408-026-01596-7

Kurniawan S; Hwang A; Doo NW; King T; Bryant C; Zhang J; Whelan K; Fani-Molky P; Kidson-Gerber G; Bosco A; Hamad N; Parmar G; Kwok F; Lai S; Ling S; Ho PJ; McCaughan G; Bryant A, 2026, 'Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study', Asia Pacific Journal of Clinical Oncology, 22, pp. 573 - 583, http://dx.doi.org/10.1111/ajco.70101

Lim KJC; Ashrafi E; Wellard C; Moore EM; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Dun K; Cooke R; Ringkowski S; Bryant A; McCaughan G; Wood E; McQuilten Z; Ho PJ; Quach H; Spencer A, 2026, 'Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry', British Journal of Haematology, 209, pp. 764 - 768, http://dx.doi.org/10.1111/bjh.70609

Montgomery E; Gorrie N; McCaughan G; Carroll AS; Rogers K; Shahi K; McDonagh J; Macdonald PS; Bart NK, 2026, 'Design and Rationale of the FICAPP Study: Frailty in Cardiac Amyloidosis: Profiling the Phenotype', Heart Lung and Circulation, 35, pp. 778 - 786, http://dx.doi.org/10.1016/j.hlc.2026.03.054

GORRIE N; HEWITT K; MCCAUGHAN G; BART N; CARROLL AS; MURPHY SM; JOYCE E, 2026, 'Burden, Impact, and Priorities in Amyloidosis: Findings from the International Amyloid Patient Experiences Survey (AMPES)', Journal of Cardiac Failure, 32, pp. 953 - 958, http://dx.doi.org/10.1016/j.cardfail.2026.03.007

Banerjee R; Dong S; McCaughan G; Mehra N; Wang B; Sperling AS; Cowan AJ; Anderson LD; Rajkumar SV; Kaur G, 2026, 'Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists', British Journal of Haematology, 208, pp. 1831 - 1835, http://dx.doi.org/10.1111/bjh.70435

Sim S; McCaughan G; Zannettino A; Ho PJ; Joshua D; Talaulikar D; Mollee P; Prince HM; Spencer A; Harrison S; Lee C; Augustson B; Kalff A; Ling S; Weber N; Yong A; Quach H, 2026, 'Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, 56, pp. 457 - 464, http://dx.doi.org/10.1111/imj.70329

Irving A; Petrie D; Harris A; Fanning L; Wood EM; Moore E; Wellard C; Waters N; Augustson B; Cook G; Gay F; McCaughan G; Mollee P; Spencer A; McQuilten ZK, 2026, 'A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data', Pharmacoeconomics, 44, pp. 83 - 95, http://dx.doi.org/10.1007/s40273-025-01554-4

Yong A; Vandyke K; Augustson B; McCaughan G; Talaulikar D; Szabo F; Prince HM; Ho PJ; Quach H; Harrison SJ; Lee CH, 2026, 'Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia', Expert Review of Hematology, 19, pp. 133 - 142, http://dx.doi.org/10.1080/17474086.2025.2574716

Reid L; Joseph J; Paterson J; Sewell W; Kane A; McCaughan G, 2026, 'A poster presentation of Epstein–Barr virus-driven T-cell lymphoma presenting with haemophagyocytic lymphohistiocytosis', Pathology, 58, pp. S63 - S63, http://dx.doi.org/10.1016/j.pathol.2026.01.276

Montgomery E; Olsen N; Gorrie N; Shahi K; Carroll A; McCaughan G; Macdonald P; Bart N, 2026, 'Association of Mild Cognitive Impairment With Physical Frailty in Transthyretin Amyloid Cardiomyopathy', Heart Lung and Circulation, 35, pp. s316 - s317, http://dx.doi.org/10.1016/j.hlc.2026.07.447

Chang W; Hsiung C; Wong S; Earls P; McCaughan G; Steel T, 2026, 'Dural - based mass presenting with spinal compression: is classic Hodgkin lymphoma ever considered in the differential diagnosis?', Pathology, 58, pp. S7 - S7, http://dx.doi.org/10.1016/j.pathol.2026.01.032

Shahi K; Montgomery E; Gorrie N; Carroll A; Macdonald P; McCaughan G; Bart N, 2026, 'Frailty Across National Amyloidosis Centre Stages in Transthyretin Amyloidosis Cardiomyopathy', Heart Lung and Circulation, 35, pp. s240, http://dx.doi.org/10.1016/j.hlc.2026.07.304

Kempler EL; Pillay R; Campion S; McCaughan G; Krigstein M, 2026, 'Loss of CD138 expression in multiple myeloma: a rare diagnostic challenge', Pathology, 58, pp. S60 - S60, http://dx.doi.org/10.1016/j.pathol.2026.01.263

Gorrie N; Hewitt K; Montgomery E; Fatkin D; McCaughan G; Bart N; Carroll A; Murphy S; Joyce E, 2026, 'Patient Diagnostic Experience With Amyloidosis: Australian Outcomes From the Amyloid Patient Experiences Survey (AMPES)', Heart Lung and Circulation, 35, pp. s255, http://dx.doi.org/10.1016/j.hlc.2026.07.333

Shahi K; Montgomery E; Gorrie N; Carroll A; Macdonald P; McCaughan G; Bart N, 2026, 'Predictors of Frailty in Transthyretin Amyloidosis Cardiomyopathy: A Real-World Australian Cohort', Heart Lung and Circulation, 35, pp. s257, http://dx.doi.org/10.1016/j.hlc.2026.07.337

Gorrie N; Geenty P; Rye E; Sivasubramaniam V; Carroll A; McCaughan G; Thomas L; Fatkin D; Bart N, 2025, 'Atrial cardiomyopathy in cardiac amyloidosis: clinical imaging and manifestations', Npj Cardiovascular Health, 2, http://dx.doi.org/10.1038/s44325-025-00043-z

Lim S-L; Mithraprabhu S; Reynolds J; Janowski W; Horvath N; Quach H; Campbell P; McCaughan G; Kim YJ; Peres Suarez T; Lee S; Wong P; Nina B; Meet P; Le K; Spencer A, 2025, 'An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.', Blood, 146, pp. 5841 - 5841, http://dx.doi.org/10.1182/blood-2025-5841

Rees M; Lasica M; Kalff A; Low M; Harrup R; Lai HC; Sidiqi MH; Wong Doo N; Routledge D; Hocking J; Campbell P; Heenan J; Horvath N; Chien N; Renwick W; McCaughan G; Eek R; Lenton D; Gazdar SG; Mazumdar D; Butcher B; Mollee P; Quach H, 2025, 'Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)', Blood, 146, pp. 4039 - 4039, http://dx.doi.org/10.1182/blood-2025-4039

King T; Acret L; Rutherford C; Tait MA; Jagger J; Sipavicius J; McCaughan G; Joshua D; White K, 2025, 'Development and Validation of a Patient-Reported Outcome Measure to Assess the Impact of Steroids in the Treatment of Myeloma: The Steroid Symptom Questionnaire–Multiple Myeloma', Seminars in Oncology Nursing, 41, http://dx.doi.org/10.1016/j.soncn.2025.151943

McCaughan G; Beer H; Bryant C; Ho PJ; King T; Lee C; Mollee P; Prince HM; Spencer A; Talaulikar D; Vandyke K; Weber N; Yong A; Harrison S; Quach H, 2025, 'Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia', Internal Medicine Journal, 55, pp. 1741 - 1751, http://dx.doi.org/10.1111/imj.70148

Banerjee R; Mohan M; Rejeski K; Puliafito BR; Cirstea DD; Kaur G; Midha S; McCaughan GJ; Kumar NM; Mehra N; Bagal B; Raje NS, 2025, 'Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels', Blood Advances, 9, pp. 4720 - 4726, http://dx.doi.org/10.1182/bloodadvances.2025016490

Lim S-L; Reynolds J; Janowski W; Quach H; Campbell P; McCaughan G; Doo NW; Lee SH; Wong P; Byard N; Le K; Nguyen A; Spencer A, 2025, 'Abstract CT214: An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone: The IBIS Study AMaRC 20-01', Cancer Research, 85, pp. ct214 - ct214, http://dx.doi.org/10.1158/1538-7445.am2025-ct214

Sandhu G; Adattini J; Armstrong Gordon E; O'Neill N; Bagnis C; Boddy AV; Chambers P; Flynn A; Hamilton B; Ibrahim K; Johnson DW; Karapetis C; Kelly A; Kerr KA; Kichenadasse G; Kliman DS; Kurkard C; Liauw W; Lucas C; Mallett AJ; Malyszko J; McCaughan G; Michael M; Mirkov S; Morris E; Pollock CA; Roberts DM; Routledge DJ; Scuderi C; Shingleton J; Shortt J; Siderov J; Sprangers B; Stein BN; Tey A; Webber K; Wichart J; Wong R; Ward RL, 2025, 'Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice', Eclinicalmedicine, 82, http://dx.doi.org/10.1016/j.eclinm.2025.103161

Lim KJC; Wellard C; Moore E; Ninkovic S; Chng WJ; Spencer A; Mollee P; Hocking J; Ho PJ; Janowski W; Kim K; McCaughan G; Dun K; McQuilten ZK; Chen F; Quach H, 2025, 'Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients', Clinical Lymphoma Myeloma and Leukemia, 25, pp. 243 - 248, http://dx.doi.org/10.1016/j.clml.2024.11.002

Chadwick V; Mills G; Tang C; Anazodo A; Dear R; Rogers R; Lavee O; Milliken S; McCaughan G; Hamad N, 2025, 'Rates of Fertility Discussions and Counseling Before, During, and After Anticancer Treatments', Jnccn Journal of the National Comprehensive Cancer Network, 23, pp. 21 - 26, http://dx.doi.org/10.6004/jnccn.2024.7068

Lasica M; Spencer A; Horvath N; Doo NW; Janowski W; Coghlan D; Wallington-Gates C; Campbell P; Lai H; McCaughan G; Weber N; Puliyali A; Wong P; Deng Y; Reynolds J; Le K; Kim YJ; Quach H, 2025, 'A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Mm): Primary Analysis. Amarc 19-02 Belacard Study', Clinical Lymphoma Myeloma and Leukemia, 25, pp. S25 - S26, http://dx.doi.org/10.1016/s2152-2650(25)03442-1

McCaughan G; Gration B; Chai R; Center J; Bray A; Kyaw W; Phan T; Croucher P, 2025, 'Romosozumab for Patients with Multiple Myeloma with Skeletal Events on Zoledronic Acid', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 25, pp. S126 - S126

Hoff FW; Banerjee R; Khan AM; McCaughan G; Wang B; Wang X; Roose J; Anderson LD; Cowan AJ; Rajkumar SV; Kaur G, 2024, 'Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis', Blood Cancer Journal, 14, http://dx.doi.org/10.1038/s41408-024-01034-6

Gration B; Wellard C; Moore E; Mollee P; Kerridge IH; Spencer A; Shetty A; Baker B; Forsyth C; Heenan J; McQuilten ZK; Wood EM; McCaughan G, 2024, 'Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)', Blood, 144, pp. 5147, http://dx.doi.org/10.1182/blood-2024-199451

Gration B; Wellard C; Moore E; Tan M; Murphy M; Lim KJC; Rowland J; Hamad N; Rajagopal R; Mollee P; Spencer A; Quach H; McCaughan G, 2024, 'Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis', Blood, 144, pp. 2385, http://dx.doi.org/10.1182/blood-2024-201790

Irving A; Petrie D; Harris A; Fanning L; Wood EM; Moore E; Wellard C; Waters N; Huynh K; Augustson B; Cook G; Gay F; McCaughan G; Mollee P; Spencer A; McQuilten ZK, 2024, 'Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry', Plos One, 19, http://dx.doi.org/10.1371/journal.pone.0308812

Montgomery E; Gorrie N; Rye E; Iglesias CK; Fatkin D; Macdonald P; Carroll A; McCaughan G; Bart N, 2024, 'Frailty Prevalence and Characteristics in a Transthyretin Amyloid Cardiomyopathy Cohort', Heart Lung and Circulation, 33, pp. s131, http://dx.doi.org/10.1016/j.hlc.2024.06.023

King T; Jagger J; Rutherford C; Acret L; Tait M-A; Sipavicius J; McCaughan G; Stapleton S; White K, 2024, 'NSO-03 Validation of the Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM) with Concurrent Symptom and Quality of Life Measurement (EORTC QLQ-C30 and MY20)', Clinical Lymphoma Myeloma and Leukemia, 24, pp. S280 - S281, http://dx.doi.org/10.1016/s2152-2650(24)02328-0

Dong S; Mehra N; McCaughan G; Wang B; Sperling A; Cowan A; Anderson L; Rajkumar SV; Kaur G; Banerjee R, 2024, 'P-380 Carfilzomib Dosing in Multiple Myeloma: An International Survey of Oncologist Practices', Clinical Lymphoma Myeloma & Leukemia, 24, pp. s252 - s253, http://dx.doi.org/10.1016/s2152-2650(24)02282-1

McCaughan G; Reynolds J; Wang T-Y; Yong A; Kim K; Huang J; Bryant C; Doo NW; Ku M; Chng WJ; Quach H, 2024, 'P-410 ALLG MM26/D1/AMN009 Novel Combinations for Orphan Myeloma (NORM) Platform Study', Clinical Lymphoma Myeloma and Leukemia, 24, pp. S271 - S271, http://dx.doi.org/10.1016/s2152-2650(24)02312-7

Gorrie N; Montgomery E; Kessler Iglesias C; Fatkin D; Carroll A; McCaughan G; Bart N, 2024, 'The Role of Cardiac Magnetic Resonance Imaging for Cardiac Staging of AL Amyloidosis', Heart, Lung and Circulation, 33, pp. S291 - S292, http://dx.doi.org/10.1016/j.hlc.2024.06.360

Montgomery E; Gorrie N; Rye E; Kessler Iglesias C; Fatkin D; Carroll A; McCaughan G; Bart N, 2024, 'The Role of Specialist Nursing Education in a Hybrid Multidisciplinary Amyloidosis Clinic', Heart, Lung and Circulation, 33, pp. S330 - S330, http://dx.doi.org/10.1016/j.hlc.2024.06.446

Chai KL; Wellard C; Thao L; Aoki N; Moore EM; Augustson BM; Bapat A; Blacklock H; Chng WJ; Cooke R; Forsyth CJ; Goh Y; Hamad N; Harrison SJ; Ho PJ; Hocking J; Kerridge I; Kim JS; Kim K; King T; McCaughan GJ; Mollee P; Morrissey CO; Murphy N; Quach H; Tan XN; Tso AC; Wong KS; Yoon S; Spencer A; Wood EM; McQuilten ZK, 2024, 'Variation in immunoglobulin use and impact on survival in myeloma', eJHaem, 5, pp. 690 - 697, http://dx.doi.org/10.1002/jha2.938

Banerjee R; Wang B; Anderson LD; McCaughan G; Mehra N; Cowan AJ; Rajkumar SV; Kaur G, 2023, 'Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians', Blood Cancer Journal, 13, http://dx.doi.org/10.1038/s41408-023-00937-0

Lasica M; Spencer A; Horvath N; Janowski W; Coghlan D; Wallington-Gates C; Campbell P; Lai HC; McCaughan G; Weber N; Puliyayil A; Wong P; Yachao D; Le K; Reynolds J; Quach H, 2023, 'A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study', Blood, 142, pp. 2012, http://dx.doi.org/10.1182/blood-2023-189005

Rajasekariah H; McCaughan G; Kris CK; Gorrie N; Milliken S; Ma D; Fay K; Withers B; Hamad N; Birch S; Keogh A; Jabbour A; Hayward C; Macdonald P; Moore J, 2023, 'Orthotopic Heart Transplantation Followed By Autologous Stem Cell Transplantation in Patients with Cardiac AL Amyloidosis: Results from a Single Centre Prospective Study', Blood, 142, pp. 3414, http://dx.doi.org/10.1182/blood-2023-184319

Quach H; Lasica M; Low M; Mollee P; Lai HC; Doo NW; Hocking J; Campbell P; Murphy NE; Sidiqi MH; Routledge D; Heenan J; Horvath N; Eek R; Renwick WEP; Lenton DS; Child LJ; McCaughan G; Butcher BE; Mazumdar D; Kalff A, 2023, 'Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)', Blood, 142, pp. 2023, http://dx.doi.org/10.1182/blood-2023-185169

Hoff FW; Banerjee R; Khan A; McCaughan G; Wang X; Roose J; Anderson LD; Cowan AJ; Rajkumar V; Kaur G, 2023, 'Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma', Blood, 142, pp. 544, http://dx.doi.org/10.1182/blood-2023-178950

Banerjee R; Kaur G; Wang B; Anderson LD; McCaughan G; Cowan AJ; Rajkumar SV, 2023, 'Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians', Blood, 142, pp. 5073, http://dx.doi.org/10.1182/blood-2023-173772

Moore E; Harrison S; Ho PJ; Irving A; King T; Mccaughan G; Mcquilten Z; Mollee P; Park S; Petrie D; Reynolds J; Rutherford C; van Tonder T; Wellard C; Wood E; Spencer A, 2023, 'PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2 TRIAL', HemaSphere, 7, pp. e68933f0 - e68933f0, http://dx.doi.org/10.1097/01.hs9.0000977464.68933.f0

Chadwick V; Kim M; Mills G; Tang C; Anazodo A; Dear R; Rodgers R; Lavee O; Milliken S; McCaughan G; Moore J; Withers B; Hamad N, 2023, 'Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care', Jnccn Journal of the National Comprehensive Cancer Network, 21, pp. 366 - 372, http://dx.doi.org/10.6004/jnccn.2022.7255

King T; Jagger J; Rutherford C; Acret L; Tait M-A; Sipavicius J; McCaughan G; Stapleton S; White K, 2023, 'NSP-09 Clinical validation of the steroid symptom questionnaire multiple myeloma (SSQ-MM) in a multi-centre study', Clinical Lymphoma Myeloma and Leukemia, 23, pp. S317 - S318, http://dx.doi.org/10.1016/s2152-2650(23)02122-5

Moore E; Harrison S; Ho PJ; Irving A; King T; McCaughan G; McQuilten Z; Mollee P; Park S; Petrie D; Reynolds J; Rutherford C; van Tonder T; Wellard C; Wood E; Spencer A, 2023, 'P-476 More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial', Clinical Lymphoma Myeloma and Leukemia, 23, pp. S301 - S302, http://dx.doi.org/10.1016/s2152-2650(23)02093-1

McCaughan GJ; Gandolfi S; Moore JJ; Richardson PG, 2022, 'Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review', British Journal of Haematology, 199, pp. 190 - 204, http://dx.doi.org/10.1111/bjh.18295

Back to profile page